Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Remdesivir

FDA-approved product (powder, intravenous), marketed as Veklury.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Remdesivir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Coronavirus infectious disease
  • COVID-19
  • Severe acute respiratory syndrome
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
FDA pharmacologic class
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB16

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Remdesivir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Remdesivir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Adaptive Dengue Antiviral Platform Trial

    NCT06551844 · start 2026-04-20

    Registered record
    Registry ID
    NCT06551844
    Conditions
    Dengue; Antiviral Drugs
    Interventions
    Molnupiravir 400 mg; VIS513 (a monoclonal antibody); Remdesivir 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-04-20
    Completion
    2030-12-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDengue; Antiviral Drugs
    InterventionMolnupiravir 400 mg; VIS513 (a monoclonal antibody); Remdesivir 100mg
    PhasePhase 2
    Registry statusRecruiting

  • A Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adults

    NCT07510529 · start 2026-04-20

    Registered record
    Registry ID
    NCT07510529
    Conditions
    Healthy Participants
    Interventions
    T-R (Test-Reference drug); R-T (Reference-Test drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-04-20
    Completion
    2026-06-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionT-R (Test-Reference drug); R-T (Reference-Test drug)
    PhasePhase 1
    Registry statusNot yet recruiting

  • Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

    NCT06683937 · start 2025-12-01

    Registered record
    Registry ID
    NCT06683937
    Conditions
    Immunocompromised Patients; SARS-CoV-2 Disease
    Interventions
    Collection of data from the patient's medical file
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-06-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmunocompromised Patients; SARS-CoV-2 Disease
    InterventionCollection of data from the patient's medical file
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV

    NCT06873633 · start 2025-07-16

    Registered record
    Registry ID
    NCT06873633
    Conditions
    Respiratory Syncytial Virus (RSV)
    Interventions
    Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-16
    Completion
    2027-02
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Syncytial Virus (RSV)
    InterventionRemdesivir
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    NCT07013474 · start 2025-07-14

    Registered record
    Registry ID
    NCT07013474
    Conditions
    COVID-19 Infection
    Interventions
    ibuzatrelvir; remdesivir; placebo for ibuzatrelvir; placebo for remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-07-14
    Completion
    2028-02-25
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Infection
    Interventionibuzatrelvir; remdesivir; placebo for ibuzatrelvir; placebo for remdesivir
    PhasePhase 3
    Registry statusRecruiting

  • Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

    NCT06792214 · start 2025-01-03

    Registered record
    Registry ID
    NCT06792214
    Conditions
    SARS CoV-2 Post-Acute Sequelae
    Interventions
    Nirmatrelvir/ritonavir; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-03
    Completion
    2027-01
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS CoV-2 Post-Acute Sequelae
    InterventionNirmatrelvir/ritonavir; Remdesivir
    PhasePhase 4
    Registry statusRecruiting

  • OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

    NCT07406217 · start 2023-04-27

    Registered record
    Registry ID
    NCT07406217
    Conditions
    COVID-19; Immunodeficiency
    Interventions
    Paxlovid 5 days; Paxlovid 10 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-27
    Completion
    2026-06-30
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; Immunodeficiency
    InterventionPaxlovid 5 days; Paxlovid 10 days
    PhasePhase 2
    Registry statusRecruiting

  • Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19

    NCT05271929 · start 2022-04-01

    Registered record
    Registry ID
    NCT05271929
    Conditions
    COVID-19
    Interventions
    Current standard of care and COVID-19 convalescent and vaccinated plasma; Current standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-04-01
    Completion
    2024-06-17
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionCurrent standard of care and COVID-19 convalescent and vaccinated plasma; Current standard of care
    PhasePhase 3
    Registry statusTerminated

  • COVID-19 International Drug Pregnancy Registry

    NCT05013632 · start 2021-12-01

    Registered record
    Registry ID
    NCT05013632
    Conditions
    Covid19
    Interventions
    Antiviral Agents; Monoclonal antibody
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-12-01
    Completion
    2027-09-30
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionAntiviral Agents; Monoclonal antibody
    PhaseNot recorded
    Registry statusRecruiting

  • Phase 2a MIB-626 vs. Placebo COVID-19

    NCT05038488 · start 2021-10-26

    Registered record
    Registry ID
    NCT05038488
    Conditions
    Covid19; Stage 1 Acute Kidney Injury
    Interventions
    MIB-626; Placebo; Home Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-10-26
    Completion
    2023-08-17
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Stage 1 Acute Kidney Injury
    InterventionMIB-626; Placebo; Home Treatment
    PhasePhase 2
    Registry statusCompleted

  • PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

    NCT05780541 · start 2021-09-15

    Registered record
    Registry ID
    NCT05780541
    Conditions
    COVID-19
    Interventions
    PF-07304814; Placebo; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-09-15
    Completion
    2023-07-14
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionPF-07304814; Placebo; Remdesivir
    PhasePhase 3
    Registry statusTerminated

  • Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care

    NCT05083000 · start 2021-08-16

    Registered record
    Registry ID
    NCT05083000
    Conditions
    COVID-19 Respiratory Infection
    Interventions
    Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-08-16
    Completion
    2022-03-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Respiratory Infection
    InterventionTopotecan
    PhasePhase 1
    Registry statusUnknown

  • OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

    NCT05222113 · start 2021-08-01

    Registered record
    Registry ID
    NCT05222113
    Conditions
    Duration of Hospitalization; Clinical Manifestation of COVID-19
    Interventions
    Remdesivir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-08-01
    Completion
    2021-09-25
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuration of Hospitalization; Clinical Manifestation of COVID-19
    InterventionRemdesivir
    PhaseNot recorded
    Registry statusCompleted

  • SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)

    NCT04978259 · start 2021-07-24

    Registered record
    Registry ID
    NCT04978259
    Conditions
    Covid19
    Interventions
    Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-07-24
    Completion
    2023-12-31
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionRemdesivir
    PhasePhase 4
    Registry statusUnknown

  • Study of Efficacy of Different Treatment Regimens of Olokizumab

    NCT05187793 · start 2021-07-08

    Registered record
    Registry ID
    NCT05187793
    Conditions
    COVID-19
    Interventions
    Olokizumab; Standard therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-07-08
    Completion
    2023-04
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionOlokizumab; Standard therapy
    PhasePhase 3
    Registry statusUnknown